Float Therapy for Fibromyalgia Clinical Trials

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

Floatation-REST has been studied for chronic pain, including fibromyalgia, with one trial showing that 84% of the intervention group were women.
A 2024 study on anxious and depressed individuals reported 85% adherence for weekly 1-hour pool-REST sessions, indicating good feasibility.
Limited evidence from two randomized controlled trials suggests floatation may reduce anxiety and improve muscle tension, blood pressure, and sleep in individuals with anxiety disorders.
This same 2024 trial on anxious and depressed participants found no serious adverse events associated with any floatation intervention.

Float therapy, also known as floatation-REST (Reduced Environmental Stimulation Therapy), is a behavioral intervention designed to lessen the external sensory input to the nervous system. This approach involves floating in a tank filled with Epsom salt-rich water, which creates a sensation of weightlessness and significantly reduces visual, auditory, and tactile stimuli. While direct, extensive clinical trials specifically on float therapy for fibromyalgia are still developing, existing research on chronic pain, anxiety, and depression provides insights into its potential benefits. For instance, a randomized controlled trial on anxious and depressed individuals, published in 2024, found that adherence to six float sessions was 85% for those assigned to weekly 1-hour pool-REST sessions, suggesting that it is a well-tolerated and feasible treatment option for these populations [https://pubmed.ncbi.nlm.nih.gov/38843272]. Studies have also explored its impact on various symptoms often associated with chronic conditions like fibromyalgia, such as pain, anxiety, and sleep difficulties.

What is Float Therapy and How Does it Work?

Float therapy, formally known as floatation-REST, or Restricted Environmental Stimulation Therapy via floatation, is a specialized behavioral intervention. Its core purpose is to attenuate, or reduce, the exteroceptive sensory input that typically reaches the nervous system [https://pubmed.ncbi.nlm.nih.gov/38843272]. This means the therapy works by minimizing external sensations like sight, sound, and touch, allowing the body and mind to enter a state of deep relaxation. The environment is carefully controlled to achieve this sensory reduction.

The Float Tank Experience

A float tank, often called a sensory deprivation tank, is a light-proof, sound-proof enclosure containing about 10-12 inches of water. This water is saturated with a high concentration of Epsom salts (magnesium sulfate). The high salt content makes the water extremely dense, allowing a person to float effortlessly on the surface, similar to how one floats in the Dead Sea. This buoyancy creates a sensation of weightlessness, which takes pressure off joints and muscles. The water is also heated to skin temperature, typically around 93.5 degrees Fahrenheit (34.7 degrees Celsius), so that after a few minutes, the sensation of where the water begins and the air ends can diminish. This combination of no light, no sound, and minimal tactile sensation aims to reduce the brain's workload, allowing for deep relaxation and a potential shift in physiological and psychological states.

Reducing Sensory Input

The concept behind floatation-REST is to provide an environment where the nervous system is not constantly processing external information. In our daily lives, our brains are bombarded with sights, sounds, and physical sensations. This constant input requires a significant amount of mental energy. By reducing these stimuli, float therapy creates a unique opportunity for the brain to rest and reallocate its resources. This reduction in sensory load is believed to contribute to the anxiolytic (anxiety-reducing) and antidepressant effects observed in some studies. When the brain is freed from processing external information, it may enter a state of theta brainwave activity, which is typically associated with deep relaxation, meditation, and creativity. This state can be profoundly restorative, both mentally and physically.

The Role of Magnesium Sulfate

The Epsom salts used in float tanks are primarily magnesium sulfate. While direct absorption rates through the skin during floating are debated, magnesium is known to play a vital role in various bodily functions. It is involved in muscle and nerve function, blood sugar control, and blood pressure regulation. Anecdotal reports from float therapy practitioners often suggest benefits related to muscle relaxation and pain reduction, which some attribute to the magnesium. However, the primary therapeutic mechanism of floatation-REST, as defined in clinical trials, is the reduction of environmental stimulation, rather than direct nutrient absorption. The sheer buoyancy provided by the salts is crucial for achieving the weightless state, which is a cornerstone of the therapy. This weightlessness helps to decompress the spine and joints, providing relief from physical stress and tension that can contribute to chronic pain conditions. The complete absence of gravity's pull allows the body to fully relax in a way that is difficult to achieve in any other environment.

Potential Mechanisms for Symptom Alleviation

The goal of floatation-REST is to provide deep relaxation and potentially alleviate symptoms of various conditions. When the body and mind are in a state of reduced environmental stimulation, several physiological changes can occur. The sympathetic nervous system, responsible for the "fight or flight" response, may calm down, allowing the parasympathetic nervous system, responsible for "rest and digest," to become more active. This shift can lead to a decrease in stress hormones like cortisol, a reduction in muscle tension, and a lowering of blood pressure. These physiological responses are often disrupted in individuals experiencing chronic pain, anxiety, and depression, making float therapy a potentially valuable intervention. The profound relaxation can also improve sleep quality, which is a common issue for many people with fibromyalgia and other chronic conditions. By allowing the mind to quiet down, float therapy can also promote mindfulness and introspection, which are beneficial for emotional regulation and stress management. The therapeutic effect is not just physical; it extends to mental and emotional well-being by providing a unique space for introspection and calm.

Can Float Therapy Help Fibromyalgia Pain?

Float therapy has been investigated as a potential intervention for chronic pain, a category that includes conditions like fibromyalgia. A randomized clinical trial specifically examined floatation Restricted Environmental Stimulation Therapy for chronic pain [https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779871]. This study aimed to understand the impact of floatation-REST on individuals experiencing persistent pain. While the research did not exclusively focus on fibromyalgia, the findings from chronic pain trials can offer insights into how floatation might affect similar conditions. Fibromyalgia is characterized by widespread chronic pain, often accompanied by fatigue, sleep problems, and mood issues, making interventions that address these symptoms particularly relevant.

Details from a Chronic Pain Study

The randomized clinical trial on chronic pain provided detailed information about its participants and methodology [https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779871]. The study included participants suffering from various forms of chronic pain, and its demographic data offers a snapshot of the population studied. When looking at the composition of the study groups, women made up a significant portion. In the intervention group, 27 out of 32 participants, or 84%, were women. In the placebo group, 32 out of 37 participants, or 86%, were women. The wait-list control group also had a notable percentage of women, with 21 out of 30 participants, or 70%, being female. These statistics are relevant because fibromyalgia is more prevalent in women, so a study with a high proportion of female participants may offer more applicable insights into the condition.

The average age of the participants in this chronic pain study also varied across the groups. The intervention group had an average age of 52.8 years, with a standard deviation of 11.5 years. The placebo group's average age was 48.8 years, with a standard deviation of 13.8 years. The wait-list control group had the highest average age at 54.2 years, with a standard deviation of 10.1 years. These age ranges suggest that the study included adults across a broad spectrum of middle to older age, which is also consistent with the typical onset and experience of chronic pain conditions like fibromyalgia. The study also looked at medication use, noting that in the intervention group, 2 (6%) used no pain medication, while 6 (19%) used nonopioid analgesics. In the placebo group, 5 (14%) used no pain medication and 6 (16%) used nonopioid analgesics. The wait-list control group had 2 (7%) using no pain medication and 3 (10%) using nonopioid analgesics. These details provide context on the baseline characteristics of individuals participating in the trial, helping us understand the population being studied.

Exploring the Impact on Pain

The randomized clinical trial on chronic pain utilized floatation Restricted Environmental Stimulation Therapy as its intervention. The primary outcomes were measured at baseline and then at 1, 12, and 24 weeks after the end of the intervention [https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779871]. This extended follow-up period is crucial for assessing not just immediate effects but also the persistence of any benefits over time. While the specific results for pain reduction in fibromyalgia patients are not detailed in the provided research, the study's focus on chronic pain generally suggests a broader interest in how floatation therapy can mitigate persistent discomfort. Fibromyalgia pain is often described as widespread, constant, and accompanied by heightened sensitivity to pressure. If floatation-REST can reduce overall pain perception or muscle tension in chronic pain populations, it could potentially offer relief for those with fibromyalgia. The reduction in sensory input might help to calm an overactive nervous system, which is believed to play a role in the amplification of pain signals in fibromyalgia. A short documentary from Clinical Floatation, published in January 2018, features individuals who feel "trapped by their physical experience of chronic pain caused by fibromyalgia," highlighting the severe impact of this condition and the search for effective therapies [https://www.clinicalfloat.org/floating-to-help-fibromyalgia]. This demonstrates a real-world interest in float therapy for fibromyalgia symptom management. For more details, see Randomized clinical trial on chronic pain.

Broader Context of Chronic Pain Research

Beyond the specific randomized clinical trial mentioned, the concept of float therapy for chronic pain and inflammation has been a subject of research, as noted by Sanctuary Float Spa [https://www.sanctuaryfloatspa.com/float-therapy-for-chronic-pain-inflammation-research-from-clinical-studies/]. This broader interest suggests that the mechanisms of floatation-REST, such as deep relaxation, reduced stress, and potential effects on muscle tension, are being considered for their application to various chronic pain conditions. The reduction of stress, in particular, is significant for fibromyalgia patients, as stress can often exacerbate their symptoms. By providing an environment conducive to profound relaxation, float therapy may help break the cycle of stress and pain. The weightless environment can also relieve physical pressure points, which are often highly sensitive in fibromyalgia patients, potentially offering a unique form of physical relief. Further research would be beneficial to precisely delineate the effects of floatation-REST on the distinct symptoms and underlying mechanisms of fibromyalgia, moving beyond general chronic pain studies to targeted investigations.

What Does Research Say About Floatation-REST for Anxiety and Depression?

Research has consistently explored the use of floatation-REST for mental health conditions, particularly anxiety and depression. Prior studies have shown that even single sessions of floatation-REST can lead to acute anxiolytic (anxiety-reducing) and antidepressant effects [https://pubmed.ncbi.nlm.nih.gov/38843272]. These positive effects are notable because they have been observed to persist for over 48 hours after a single session, suggesting a lasting impact beyond the immediate float experience. This indicates that floatation-REST is not just a temporary calming measure but may induce more sustained changes in mood and anxiety levels.

Feasibility and Safety of Repeated Sessions

While the acute effects of single sessions were known, the feasibility of using floatation-REST as a repeated intervention in anxious and depressed populations had not been thoroughly investigated until recently. A randomized controlled safety and feasibility trial, published in 2024 by McKenna M Garland et al., addressed this gap [https://pubmed.ncbi.nlm.nih.gov/38843272]. This study aimed to determine if individuals with anxiety and depression could consistently engage with float therapy over multiple sessions and if it remained safe. The trial involved 75 individuals who were ultimately randomized after an initial screening of 1,715 potential participants. These individuals were assigned to complete six sessions of floatation-REST in different formats, or an active comparator.

The study's primary outcome was feasibility, assessed by an 80% rate of adherence to the assigned intervention. The results were encouraging: six-session adherence was 85% for participants in the pool-REST group, who completed weekly 1-hour float sessions. The average number of sessions completed in this group was 5.1, with a standard deviation (SD) of 1.8. For those in the pool-REST preferred group, who had flexibility in session duration and frequency, adherence was even higher at 89%, with an average of 5.3 sessions completed (SD = 1.6). This high adherence rate demonstrates that floatation-REST is a practical and acceptable intervention for individuals dealing with anxiety and depression, suggesting that people are willing and able to incorporate it into their routine. In contrast, the active comparator group, chair-REST (weekly 1-hour sessions in a Zero Gravity chair), showed a lower adherence rate of 74%, with an average of 4.4 sessions (SD = 2.5), highlighting the comparative appeal of floatation.

Session Duration and Impact

The study also tracked the mean session durations across the different groups. Participants in the standard pool-REST group spent an average of 53.0 minutes in their float sessions, with a standard deviation of 12.3 minutes. The pool-REST preferred group, which allowed for flexible session lengths, showed a longer average duration of 75.4 minutes (SD = 29.4). This flexibility allowed participants to tailor their experience, potentially enhancing its effectiveness and appeal. The chair-REST group had a mean session duration of 58.4 minutes (SD = 4.3).

McKenna M Garland et al. stated, "Prior studies in anxious and depressed individuals demonstrated that single sessions of floatation-REST are safe, well-tolerated, and associated with an acute anxiolytic and antidepressant effect that persists for over 48 hours" [https://pubmed.ncbi.nlm.nih.gov/38843272]. This quote underscores the established immediate benefits and provides context for why investigating repeated sessions was important. The persistence of these effects for over 48 hours after a single session suggests that floatation-REST could offer more than just transient relief, potentially contributing to a cumulative improvement in mental well-being over time with repeated use. This is particularly relevant for chronic conditions where sustained relief is critical.

Broader Mental Health Context

Beyond specific trials, the potential for floatation-REST to address symptoms associated with anxiety and depression has been noted in broader reviews. Limited evidence from two randomized controlled trials suggests that floatation with restricted environmental stimulation therapy may provide some potential benefits in reducing anxiety [https://www.ncbi.nlm.nih.gov/books/NBK594333/]. These benefits extend to improving various symptoms commonly associated with anxiety, including muscle tension, difficulties in emotion regulation, sleep difficulties, and even depression. The ability of floatation therapy to mitigate these interconnected symptoms makes it a promising area of study for individuals whose conditions, like fibromyalgia, often co-occur with or are exacerbated by anxiety and depression. The profound relaxation induced by floatation-REST can directly address muscle tension, a common complaint in both anxiety and fibromyalgia. By improving sleep quality, float therapy can also indirectly alleviate symptoms of depression and improve overall mood and energy levels. The reduction in sensory input allows the mind to quiet, fostering a state of calm that can help individuals regulate their emotions more effectively.

Is Float Therapy Safe and Well-Tolerated?

The safety and tolerability of float therapy are critical considerations for its adoption as a therapeutic intervention. Multiple clinical trials have consistently reported positive findings regarding these aspects, indicating that floatation-REST is generally safe for participants. Importantly, these studies have identified no serious adverse events or negative side effects directly associated with the therapy. This consistent reporting across different trials strengthens the evidence for its safety profile.

Evidence from Clinical Trials

The 2024 randomized controlled safety and feasibility trial on anxious and depressed individuals, conducted by McKenna M Garland et al., specifically assessed safety as a key outcome [https://pubmed.ncbi.nlm.nih.gov/38843272]. The study found no serious adverse events associated with any of the interventions, which included weekly 1-hour float sessions (pool-REST), flexible float sessions (pool-REST preferred), and weekly 1-hour sessions in a Zero Gravity chair (chair-REST). This finding is significant because it covers different formats of the therapy and an active control, demonstrating safety across various applications. The absence of serious adverse events provides reassurance that floatation-REST does not pose significant health risks to participants, even when administered repeatedly over several sessions. This trial's robust methodology, including a large initial screening pool of 1,715 individuals, provides strong support for its safety conclusions.

In addition to the absence of serious adverse events, the tolerability of float therapy was also high. The study reported that positive experiences were endorsed more commonly than negative ones. Furthermore, these positive experiences were rated at higher levels of intensity compared to any negative experiences. This suggests that participants not only found the therapy safe but also genuinely beneficial and enjoyable, which is crucial for adherence and long-term engagement with any treatment. The study also examined dropout rates at the end of the intervention period and found no significant differences between the treatment conditions. This indicates that participants were not dropping out of the float therapy groups at a higher rate than the control group, further supporting its tolerability and acceptability among the target population. High tolerability is a significant advantage for any intervention, as it increases the likelihood that individuals will complete the recommended course of treatment and experience its full potential benefits. For more details, see Floatation-REST trial in anxious and depressed individuals.

Broader Safety Assessments

Beyond the 2024 trial, other reviews and trials have echoed these safety findings. A review on floatation therapy for mental health conditions, for example, also concluded that "both trials reported no serious adverse events or negative side effects associated with the floatation therapy" [https://www.ncbi.nlm.nih.gov/books/NBK594333/]. This consistent reporting across independent assessments reinforces the safety profile of floatation-REST. The mechanisms of float therapy, which involve external sensory reduction rather than internal physiological manipulation through medication, inherently carry a lower risk of systemic side effects. The primary concerns, if any, often relate to individual comfort or psychological responses to the unique environment, such as claustrophobia, but these are typically managed through proper orientation and support.

The low risk associated with float therapy makes it an attractive option for individuals seeking complementary or alternative treatments, especially those who may be sensitive to pharmacological interventions or prefer non-pharmacological approaches. For conditions like fibromyalgia, where patients often manage multiple symptoms and may be on various medications, an intervention with a strong safety record and minimal side effects is particularly valuable. The ability to achieve deep relaxation and potential symptom relief without the burden of adverse reactions is a significant benefit. Overall, the available clinical evidence strongly supports floatation-REST as a safe and well-tolerated intervention, with participants generally reporting positive experiences and no serious health risks.

Are There Other Mental Health Benefits from Float Therapy?

Beyond its impact on anxiety and depression, float therapy has shown potential to offer a range of other mental health benefits, particularly in areas related to stress response, emotional regulation, and specific psychiatric conditions. The unique environment of reduced environmental stimulation therapy (REST) allows for deep relaxation, which can have cascading positive effects on various aspects of mental well-being. This is particularly relevant for individuals with complex conditions like fibromyalgia, where mental and physical health are often intertwined.

Impact on Anxiety-Related Symptoms

Limited evidence from two randomized controlled trials suggests that floatation with restricted environmental stimulation therapy may provide some potential benefits in reducing anxiety [https://www.ncbi.nlm.nih.gov/books/NBK594333/]. These benefits are not solely confined to the feeling of anxiety itself but extend to many of the symptoms associated with anxiety disorders. For instance, floatation therapy has been linked to improvements in muscle tension, a common physical manifestation of anxiety and a pervasive symptom in fibromyalgia. By promoting deep physical relaxation, float therapy can help alleviate the chronic muscle tightness that many individuals experience.

Furthermore, the therapy has been observed to influence blood pressure, which can be elevated during periods of stress and anxiety. While not a direct treatment for hypertension, the calming effects of floating may contribute to a more balanced physiological state. Difficulties in emotion regulation are also a key challenge for individuals with anxiety and other mental health conditions. By fostering a state of calm and introspection, floatation therapy may help individuals develop a greater capacity to manage and process their emotions. This ability to regulate emotions more effectively can lead to improved coping strategies and a reduction in emotional distress.

Sleep difficulties are another significant symptom frequently associated with anxiety and depression, and they are almost universally reported by individuals with fibromyalgia. The profound relaxation induced by float therapy has shown promise in improving sleep quality. When the body and mind are able to fully unwind in the sensory-reduced environment, it can reset sleep patterns and promote more restful sleep. Improved sleep, in turn, can have a positive ripple effect on mood, energy levels, and overall mental resilience. Finally, the same limited evidence from these two trials also points to potential benefits in reducing symptoms of depression in individuals with anxiety disorders, highlighting the interconnectedness of these mental health challenges.

Addressing Specific Psychiatric Conditions

Floatation-REST has also been investigated for its efficacy in addressing symptoms of other specific psychiatric conditions. For example, a randomized clinical efficacy trial examined the impact of floatation therapy on body image disturbance and anxiety in inpatients with anorexia nervosa (AN) [https://pubmed.ncbi.nlm.nih.gov/37936658/]. Anorexia nervosa is a severe psychiatric disorder characterized by body image distortion and high levels of anxiety, and it has one of the highest mortality rates among psychiatric conditions. This study aimed to explore a novel non-pharmacological treatment for these core features of AN. While the specifics of the trial's outcomes are not detailed in the provided research, the mere fact that floatation-REST is being explored for such a complex and severe condition suggests its perceived potential for broad mental health applications. The ability to alleviate body image disturbance and anxiety in a population as vulnerable as AN inpatients would represent a significant therapeutic breakthrough. This research direction highlights the versatility of floatation-REST as an intervention that can be tailored to address specific psychological symptoms across a spectrum of mental health diagnoses. The reduction of external stimuli may help individuals detach from distressing thoughts and perceptions, including those related to body image, allowing for a more internal and mindful experience.

Current Limitations and Future Research Directions

While existing research on float therapy, particularly floatation-REST, shows promising results for various conditions, including chronic pain, anxiety, and depression, it is important to acknowledge the current limitations in the evidence base. These limitations highlight areas where further scientific inquiry is needed to fully understand the scope, efficacy, and practical application of float therapy. Addressing these gaps will be crucial for establishing float therapy as a mainstream, evidence-based intervention.

Gaps in Economic and Guideline Evidence

One significant limitation is the lack of information regarding the cost-effectiveness of floatation therapy for mental health conditions. Currently, "no evidence was found on the cost-effectiveness of floatation therapy for the treatment of mental health conditions" [https://www.ncbi.nlm.nih.gov/books/NBK594333/]. This means that while studies may demonstrate clinical benefits, there is not enough data to determine if these benefits are economically viable when compared to other treatments or if they offer a good return on investment for individuals, healthcare systems, or insurers. Understanding cost-effectiveness is crucial for wider adoption, as it directly impacts accessibility and policy decisions. Without this information, it is difficult for healthcare providers or policymakers to recommend float therapy as a primary or adjunctive treatment based on economic grounds. For more details, see Floatation Therapy for Mental Health Conditions.

Furthermore, there is a recognized absence of established guidelines. Specifically, "no evidence-based guidelines with recommendations regarding the use of floatation therapy for the treatment of mental health conditions were identified" [https://www.ncbi.nlm.nih.gov/books/NBK594333/]. This lack of guidelines means that there are no standardized protocols for how float therapy should be administered for specific conditions, including dosage (frequency and duration of sessions), ideal candidate profiles, or integration with other therapies. The absence of such guidelines can lead to inconsistent application of the therapy and makes it challenging for practitioners to offer standardized, evidence-informed care. Developing these guidelines would require a larger body of rigorous research, including comprehensive randomized controlled trials.

Need for More Targeted and Long-Term Research

Many existing studies, while valuable, may not directly address specific chronic pain conditions like fibromyalgia with the depth required. For instance, while a randomized clinical trial on chronic pain included a significant number of women (84% in the intervention group), it did not specifically isolate fibromyalgia patients for detailed analysis [https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779871]. Future research should aim for targeted studies on specific chronic pain populations, such as those with fibromyalgia, to understand the precise mechanisms and benefits for their unique symptom profiles. This would involve larger sample sizes and methodologies designed to capture fibromyalgia-specific outcomes like tender point count, widespread pain index, and symptom severity scales.

Moreover, while acute effects and short-term feasibility have been studied, there is a need for more research into the long-term effects of floatation therapy. Understanding how benefits persist over months or even years, and what maintenance protocols might be necessary, is essential for truly integrating float therapy into chronic disease management. This includes investigating the optimal number of sessions, the ideal frequency, and whether booster sessions are required to sustain improvements. Longitudinal studies with extended follow-up periods are critical for addressing these questions. The current research has shown that single sessions can have effects lasting over 48 hours, and repeated sessions are feasible, but the long-term impact on chronic pain or mental health conditions requires more dedicated investigation.

Methodological Enhancements

Future research would also benefit from methodological enhancements. This includes larger, multi-center randomized controlled trials (RCTs) to increase generalizability and statistical power. Blinding participants and researchers, where possible, to reduce bias, and using objective outcome measures alongside self-reported scales, would strengthen the evidence. Comparing float therapy against other active treatments, beyond just placebo or wait-list controls, would also provide a clearer picture of its comparative effectiveness. For example, comparing float therapy to other non-pharmacological interventions commonly used for fibromyalgia, such as exercise or cognitive behavioral therapy, could offer valuable insights into its unique contributions. Exploring the physiological changes that occur during and after floatation-REST, such as changes in brain activity, hormone levels, and inflammatory markers, could elucidate the underlying mechanisms through which the therapy exerts its effects. This deeper understanding could lead to more refined and targeted applications of float therapy in the future.

Frequently Asked Questions

What is floatation-REST?

Floatation-REST, or Reduced Environmental Stimulation Therapy via floatation, is a behavioral intervention designed to significantly lessen sensory input to the nervous system. It involves floating in a tank of highly saline water, typically set to skin temperature, in a light-proof and sound-proof environment. This process aims to create a state of deep relaxation and reduce external stimuli. A 2024 study on anxious and depressed individuals confirmed that floatation-REST sessions are safe and well-tolerated [https://pubmed.ncbi.nlm.nih.gov/38843272].

How many float sessions are typically studied in trials?

Clinical trials often investigate multiple sessions to assess feasibility and sustained effects. For example, a 2024 randomized controlled trial involved participants completing six sessions of floatation-REST over a period of time. In this study, six-session adherence was 85% for those assigned to weekly 1-hour pool-REST sessions, with participants averaging 5.1 sessions [https://pubmed.ncbi.nlm.nih.gov/38843272].

Is float therapy covered by insurance?

The provided research does not offer information on the cost-effectiveness of floatation therapy or whether it is covered by insurance. A review on floatation therapy for mental health conditions explicitly stated that "No evidence was found on the cost-effectiveness of floatation therapy for the treatment of mental health conditions" [https://www.ncbi.nlm.nih.gov/books/NBK594333/]. Therefore, individuals interested in float therapy should inquire directly with their insurance providers.

Are there any serious side effects of floatation therapy?

Clinical trials have consistently reported a strong safety profile for float therapy. The 2024 randomized controlled trial on anxious and depressed individuals reported "no serious adverse events associated with any intervention" [https://pubmed.ncbi.nlm.nih.gov/38843272]. Additionally, a review on mental health conditions noted that "both trials reported no serious adverse events or negative side effects associated with the floatation therapy" [https://www.ncbi.nlm.nih.gov/books/NBK594333/].

Can float therapy help with chronic pain beyond fibromyalgia?

Yes, float therapy has been investigated for general chronic pain. A randomized clinical trial specifically examined "Flotation Restricted Environmental Stimulation Therapy for Chronic Pain" [https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779871]. While the specific outcomes for pain reduction are not detailed in the provided research, the study's focus indicates that floatation-REST is considered a potential intervention for a broader range of chronic pain conditions.